参考来源: 1.Byrski T, Huzarski T, Dent R, et al:Pathologic complete response to neoadjuvant cisplatin inBRCA1 positive breast cancer patients. Breast Cancer Res Treat 147:401-5, 2014 2.KaufmanB,ShapiraFrommer R, Schmutzler RK, et al:...
3.Koobotse M, Holly J, Perks C. Elucidating the Novel BRCA1 Function as a Non-Genomic Metabolic Restraint in ER-Positive Breast Cancer Cell Lines. Oncotarget (2018) 9:33562–76. doi: 10.18632/oncotarget.26093 4.Koobotse MO, Schmidt D, Holly JMP, Perks ...
Byrski T, Huzarski T, Dent R, et al. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2014;147(2):401-405. von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and H...
7.Byrski T, Huzarski T, Dent R, et al: Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Can- cer Res Treat 147:401-405, 2014 8.Byrski T, Gronwald J, Huzarski T, et al: Path- ologic complete response rates in young women with BRCA1...
Bilateral Mastectomy Not Tied to Better Survival in BRCA1-Positive Breast Cancer— However, the surgery did reduce risk of contralateral breast cancerby Wayne Kuznar, Contributing Writer December 9, 2023 Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or...
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2009; 115 (2):359–363. doi: 10.1007/s10549-008-0128-9. [ Cross Ref ]Gronwald J, Byrski T, Huzarski T, et al. Neoadjuvant therapy with cisplatin in BRCA1-positive breast ...
产品名称 Recombinant Breast Cancer Susceptibility Protein 1 (BRCA1) 产品规格 50µg 200µg 1mg 5mg 有效成分含量 99% 是否进口 是 用途范围 Positive Control; Immunogen; SDS-PAGE; WB. 如果需要有生物活性的蛋白,请参见活性蛋白。 包装规格 0.5kg 来源 原核表达 片段与标签 Gln19~Val83 with...
Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol 2005;18:1321-8.M Laakso,N Loman,A Borg,J Isola.Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Modern Pathology . 2005...
Purpose;To estimate 10-year overall survival (OS) rates for patients with early-onset breast cancer, with and without a BRCA1 mutation, and to identify prognostic factors among those with BRCA1-positive breast cancer.Patients and Methods;A total of 3,345 women with stage I to III breast can...
I’ve just undergone my 7th surgery in 9 months. My body has had it, and I’m thinking about how this cancer could’ve been prevented if I had known I was #brca1 positive before. Immediately following my double mastectomy with expander placement. So sore. So out of it. My chest feel...